TWD 79.5
(-3.52%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 2.34 Billion TWD | 27.73% |
2022 | 1.83 Billion TWD | 3.07% |
2021 | 1.78 Billion TWD | 2.84% |
2020 | 1.73 Billion TWD | -1.51% |
2019 | 1.76 Billion TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 2.46 Billion TWD | 4.79% |
2024 Q2 | 2.8 Billion TWD | 14.16% |
2023 Q4 | 2.34 Billion TWD | 15.4% |
2023 FY | 2.34 Billion TWD | 27.73% |
2023 Q3 | 2.03 Billion TWD | 5.12% |
2023 Q2 | 1.93 Billion TWD | 5.0% |
2023 Q1 | 1.84 Billion TWD | 0.28% |
2022 FY | 1.83 Billion TWD | 3.07% |
2022 Q4 | 1.83 Billion TWD | 0.0% |
2021 FY | 1.78 Billion TWD | 2.84% |
2020 FY | 1.73 Billion TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
DIVA Laboratories, Ltd. | 1.24 Billion TWD | -88.838% |
Genetics Generation Advancement Corp. | 595.05 Million TWD | -294.694% |
Welgene Biotech Co.,Ltd. | 548.16 Million TWD | -328.456% |
Puriblood Medical Co., Ltd. | 265.51 Million TWD | -784.57% |
TFBS Bioscience Inc. | 1.44 Billion TWD | -62.194% |